Study of Once Daily Levemir (SOLVE™): Insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice

K. Khunti, T. Damci, L. Meneghini, C. Y. Pan, J. F. Yale

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Aims: The aim of this analysis is to determine the timing of insulin initiation in routine clinical practice, especially in relation to glycaemic control and use of oral antidiabetic drugs (OADs). Methods: Study of Once Daily Levemir was a 24-week international observational study involving 10 countries which evaluated the safety and effectiveness of initiating once-daily insulin detemir in people with type 2 diabetes mellitus (T2DM) being treated with one or more OADs (clinical trial number NCT00825643 and NCT00740519). Results: A total of 17 374 participants were enrolled in the study: aged 62 ± 12 years, 53% male, T2DM duration 10 ± 7 years, body mass index 29.3 ± 5.4 kg/m2. Pre-insulin HbA1c was 8.9 ± 1.6%. The proportion of patients with HbA1c ≥9.0% ranged from 64% (UK) to 23% (Poland). Pre-insulin OAD treatment included metformin (81%), sulphonylureas (59%), glinides (16%), thiazolidinediones (TZD) (12%), α-glucosidase inhibitors (12%) and dipeptidyl peptidase (DPP)-IV inhibitors (7%). The mean starting dose of insulin detemir for the total cohort was 0.16 ± 0.09 U/kg. Differences in OAD use and insulin doses at initiation were evident among participating countries. The largest proportional changes in OAD prescribing at insulin initiation were seen with glinides (+15%), sulphonylureas (-19%), TZD (-31%) and DPP-IV inhibitors (-28%). Conclusions: Despite well-documented benefits of timely glycaemic control and consensus guidelines encouraging earlier use of insulin, considerable clinical inertia exists with respect to initiating appropriate insulin therapy in people with T2DM. Considerable regional differences exist in the timing of insulin initiation and in the use of OADs.

Original languageEnglish (US)
Pages (from-to)654-661
Number of pages8
JournalDiabetes, Obesity and Metabolism
Volume14
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Type 2 Diabetes Mellitus
Hypoglycemic Agents
Insulin
Dipeptidyl-Peptidase IV Inhibitors
Thiazolidinediones
Glucosidases
Drug Prescriptions
Insulin Detemir
Metformin
Poland
Observational Studies
Body Mass Index
Clinical Trials
Guidelines
Safety
Therapeutics

Keywords

  • Clinical inertia
  • Epidemiology
  • Insulin therapy
  • Observational study
  • Oral antidiabetic drug therapy
  • Treatment guidelines
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Study of Once Daily Levemir (SOLVE™) : Insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. / Khunti, K.; Damci, T.; Meneghini, L.; Pan, C. Y.; Yale, J. F.

In: Diabetes, Obesity and Metabolism, Vol. 14, No. 7, 07.2012, p. 654-661.

Research output: Contribution to journalArticle

@article{83be626ddac448628a1a11640c60a651,
title = "Study of Once Daily Levemir (SOLVE™): Insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice",
abstract = "Aims: The aim of this analysis is to determine the timing of insulin initiation in routine clinical practice, especially in relation to glycaemic control and use of oral antidiabetic drugs (OADs). Methods: Study of Once Daily Levemir was a 24-week international observational study involving 10 countries which evaluated the safety and effectiveness of initiating once-daily insulin detemir in people with type 2 diabetes mellitus (T2DM) being treated with one or more OADs (clinical trial number NCT00825643 and NCT00740519). Results: A total of 17 374 participants were enrolled in the study: aged 62 ± 12 years, 53{\%} male, T2DM duration 10 ± 7 years, body mass index 29.3 ± 5.4 kg/m2. Pre-insulin HbA1c was 8.9 ± 1.6{\%}. The proportion of patients with HbA1c ≥9.0{\%} ranged from 64{\%} (UK) to 23{\%} (Poland). Pre-insulin OAD treatment included metformin (81{\%}), sulphonylureas (59{\%}), glinides (16{\%}), thiazolidinediones (TZD) (12{\%}), α-glucosidase inhibitors (12{\%}) and dipeptidyl peptidase (DPP)-IV inhibitors (7{\%}). The mean starting dose of insulin detemir for the total cohort was 0.16 ± 0.09 U/kg. Differences in OAD use and insulin doses at initiation were evident among participating countries. The largest proportional changes in OAD prescribing at insulin initiation were seen with glinides (+15{\%}), sulphonylureas (-19{\%}), TZD (-31{\%}) and DPP-IV inhibitors (-28{\%}). Conclusions: Despite well-documented benefits of timely glycaemic control and consensus guidelines encouraging earlier use of insulin, considerable clinical inertia exists with respect to initiating appropriate insulin therapy in people with T2DM. Considerable regional differences exist in the timing of insulin initiation and in the use of OADs.",
keywords = "Clinical inertia, Epidemiology, Insulin therapy, Observational study, Oral antidiabetic drug therapy, Treatment guidelines, Type 2 diabetes mellitus",
author = "K. Khunti and T. Damci and L. Meneghini and Pan, {C. Y.} and Yale, {J. F.}",
year = "2012",
month = "7",
doi = "10.1111/j.1463-1326.2012.01602.x",
language = "English (US)",
volume = "14",
pages = "654--661",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Study of Once Daily Levemir (SOLVE™)

T2 - Insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice

AU - Khunti, K.

AU - Damci, T.

AU - Meneghini, L.

AU - Pan, C. Y.

AU - Yale, J. F.

PY - 2012/7

Y1 - 2012/7

N2 - Aims: The aim of this analysis is to determine the timing of insulin initiation in routine clinical practice, especially in relation to glycaemic control and use of oral antidiabetic drugs (OADs). Methods: Study of Once Daily Levemir was a 24-week international observational study involving 10 countries which evaluated the safety and effectiveness of initiating once-daily insulin detemir in people with type 2 diabetes mellitus (T2DM) being treated with one or more OADs (clinical trial number NCT00825643 and NCT00740519). Results: A total of 17 374 participants were enrolled in the study: aged 62 ± 12 years, 53% male, T2DM duration 10 ± 7 years, body mass index 29.3 ± 5.4 kg/m2. Pre-insulin HbA1c was 8.9 ± 1.6%. The proportion of patients with HbA1c ≥9.0% ranged from 64% (UK) to 23% (Poland). Pre-insulin OAD treatment included metformin (81%), sulphonylureas (59%), glinides (16%), thiazolidinediones (TZD) (12%), α-glucosidase inhibitors (12%) and dipeptidyl peptidase (DPP)-IV inhibitors (7%). The mean starting dose of insulin detemir for the total cohort was 0.16 ± 0.09 U/kg. Differences in OAD use and insulin doses at initiation were evident among participating countries. The largest proportional changes in OAD prescribing at insulin initiation were seen with glinides (+15%), sulphonylureas (-19%), TZD (-31%) and DPP-IV inhibitors (-28%). Conclusions: Despite well-documented benefits of timely glycaemic control and consensus guidelines encouraging earlier use of insulin, considerable clinical inertia exists with respect to initiating appropriate insulin therapy in people with T2DM. Considerable regional differences exist in the timing of insulin initiation and in the use of OADs.

AB - Aims: The aim of this analysis is to determine the timing of insulin initiation in routine clinical practice, especially in relation to glycaemic control and use of oral antidiabetic drugs (OADs). Methods: Study of Once Daily Levemir was a 24-week international observational study involving 10 countries which evaluated the safety and effectiveness of initiating once-daily insulin detemir in people with type 2 diabetes mellitus (T2DM) being treated with one or more OADs (clinical trial number NCT00825643 and NCT00740519). Results: A total of 17 374 participants were enrolled in the study: aged 62 ± 12 years, 53% male, T2DM duration 10 ± 7 years, body mass index 29.3 ± 5.4 kg/m2. Pre-insulin HbA1c was 8.9 ± 1.6%. The proportion of patients with HbA1c ≥9.0% ranged from 64% (UK) to 23% (Poland). Pre-insulin OAD treatment included metformin (81%), sulphonylureas (59%), glinides (16%), thiazolidinediones (TZD) (12%), α-glucosidase inhibitors (12%) and dipeptidyl peptidase (DPP)-IV inhibitors (7%). The mean starting dose of insulin detemir for the total cohort was 0.16 ± 0.09 U/kg. Differences in OAD use and insulin doses at initiation were evident among participating countries. The largest proportional changes in OAD prescribing at insulin initiation were seen with glinides (+15%), sulphonylureas (-19%), TZD (-31%) and DPP-IV inhibitors (-28%). Conclusions: Despite well-documented benefits of timely glycaemic control and consensus guidelines encouraging earlier use of insulin, considerable clinical inertia exists with respect to initiating appropriate insulin therapy in people with T2DM. Considerable regional differences exist in the timing of insulin initiation and in the use of OADs.

KW - Clinical inertia

KW - Epidemiology

KW - Insulin therapy

KW - Observational study

KW - Oral antidiabetic drug therapy

KW - Treatment guidelines

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84861860599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861860599&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1326.2012.01602.x

DO - 10.1111/j.1463-1326.2012.01602.x

M3 - Article

C2 - 22443213

AN - SCOPUS:84861860599

VL - 14

SP - 654

EP - 661

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 7

ER -